SP1 and ovarian carcinoma: Since Sp1-driven transcription plays an integral role in the pathogenesis of ovarian cancer and platinum-resistance mechanisms [38,42,66], and mithramycin has demonstrated a potent ability to inhibit Sp1, mithramycin or its more selective, safer analogs could be a potential strategy to overcome platinum resistance.